The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
The mortality of chronic heart failure patients remains high, in spite of recent treatment. RhNRG-1(recombinant human neuregulin-1)directly work on the cardiomyocyte and restored the normal structure and function of it. Both the preclinical trial and phase II clinical trail have confirmed that rhNRG-1 effectively enhance the heart function and reverse the remodeling of left ventricular in heart failure animals and humans. In this study, we will evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
331
all cause mortality
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
General Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
The First Hospital affiliated to Lanzhou University
Lanzhou, Gansu, China
Haikou Municipal Peoples Hospital
Haikou, Hainan, China
Bethune International Peace Hospital
Shijiazhuang, Hebei, China
Teda International Cardiovascular Hospital
Tianjin, Hebei, China
Daqing Oilfield General Hospital
Daqing, Heilongjiang, China
The First Hospital of Harbin Medical University
Haerbin, Heilongjiang, China
The First hospital affiliated to Zhengzhou University
Zhengzhou, Henan, China
Zhongnan Hospital of Wuhan University
Wuchang, Hubei, China
Tongji Hospital Affiliated to Huazhong University of Science and Technology
Wuhan, Hubei, China
...and 33 more locations